Treatment Options and Reversibility
At a Glance
Treatment for ovarian stromal hyperthecosis depends on menopause status, surgical risk, and fertility goals. Surgery can quickly lower testosterone, but some hair, voice, or clitoral changes may persist; medicines and metabolic care are alternatives.
Deciding on a treatment for ovarian stromal hyperthecosis depends largely on your stage of life, operative risk, and your personal health goals. Because the condition is driven by overactive cells in the ovaries, the most effective treatments focus on either removing those cells or “turning off” their hormone production [1][2].
Treatment for Postmenopausal Patients
For those who have already completed menopause, bilateral salpingo-oophorectomy (BSO)—the surgical removal of both ovaries and fallopian tubes—is often recommended as a definitive treatment option, though decisions must account for surgical risk and patient preference [1][2].
- Why Surgery? Surgery is considered definitive because it removes the source of excess testosterone. Perhaps more importantly, it allows a pathologist to examine the tissue under a microscope. This confirms the tissue diagnosis and ensures that a small, hidden tumor was not the cause [1][3].
- The Recovery Timeline: After surgery, testosterone levels typically drop very quickly, often normalizing within 4 to 8 weeks [4][5].
- Symptom Improvement and Reversibility: While blood levels drop fast, physical changes take much longer to reverse, and some may be permanent. You may see improvement in skin and hair growth within a few months, but it can take 8 months or more for hirsutism (excess facial/body hair) to significantly subside [6][5]. Existing terminal (dark, coarse) hair often requires cosmetic treatments like laser or electrolysis. Additionally, voice deepening or clitoromegaly (clitoral enlargement) may be permanent and not reverse after surgery [6].
Treatment for Premenopausal Patients
If you are younger and wish to preserve your fertility or avoid early menopause, your doctors will likely discuss medical management managed by a specialist, though evidence for these treatments is limited [1][7]. Patients who have their ovaries removed prior to natural menopause will also need separate discussions regarding cardiovascular and bone health and whether hormone replacement is appropriate.
- GnRH Agonists: Medications like leuprolide work by “shutting down” the signal from your brain that tells the ovaries to produce hormones. This can significantly lower testosterone levels [8][9]. Important Limitations: These medications can cause an initial testosterone flare, hot flashes, vaginal dryness, and bone loss over time. Their long-term effectiveness in hyperthecosis is variable.
- Combined Oral Contraceptives: Birth control pills are often used alongside other treatments to help regulate your cycle and provide a steady, low level of estrogen, though they carry contraindications that must be evaluated [10][7].
- Antiandrogens: Medications like spironolactone do not lower testosterone levels directly, but they block the hormone from “locking into” your hair follicles and skin cells. This helps reduce hair growth and acne, though it can take 6 to 18 months to see the full effect on hair [1][11]. Important Safety Note: Spironolactone requires potassium and kidney function monitoring, and you must strictly prevent pregnancy due to the risk of fetal harm.
- Ovarian-Sparing Surgery: In very rare cases, surgeons may attempt to remove only the affected stroma while leaving the rest of the ovary intact. This is not a standard procedure and is usually only considered in specialized centers for patients who strongly desire to maintain fertility [12].
Managing the Insulin Connection
Regardless of your age, treating the hormonal side of hyperthecosis is often paired with addressing metabolic health. Because this condition is so closely tied to insulin resistance, your doctor may recommend metabolic support [2][1]:
- Metformin: This medication helps your body use insulin more effectively. While it may not “cure” the ovarian issue on its own or reliably normalize testosterone, it is often used to manage blood sugar, diabetes, or metabolic risks [1][13].
- Lifestyle Measures: Focusing on a balanced diet and regular physical activity can help lower insulin levels and improve overall cardiovascular health [1].
What If Medical Treatment Isn’t Enough?
If you are using medical management but your testosterone levels stay high after several months, or if your symptoms continue to worsen rapidly, your care team may revisit the idea of surgery [1]. This is done to ensure your safety and to provide the definitive diagnosis that only pathology can offer.
Common questions in this guide
What is the usual treatment for ovarian hyperthecosis after menopause?
Which symptoms of ovarian hyperthecosis can improve after surgery?
What treatment options are available if I want to preserve fertility?
Does spironolactone lower testosterone in ovarian hyperthecosis?
What side effects can GnRH agonists cause?
Can metformin cure ovarian stromal hyperthecosis?
When might surgery be reconsidered if medical treatment is not working?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.If I am postmenopausal, what are the specific surgical risks of a bilateral oophorectomy for me?
- 2.If we choose surgery, what is your approach for ensuring a pathologist evaluates the tissue to confirm it isn't an occult tumor?
- 3.For a premenopausal patient, what are the side effects and long-term bone health risks of GnRH agonist therapy?
- 4.If I take spironolactone, how often will we monitor my potassium and kidney function?
- 5.Which of my current physical symptoms (like hair growth or voice changes) are likely to be permanent, even after treatment?
- 6.Given the metabolic risks, should we also coordinate with an endocrinologist or a primary care doctor?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism.
Meczekalski B, Szeliga A, Maciejewska-Jeske M, et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2021; (37(8)):677-682 doi:10.1080/09513590.2021.1903419.
PMID: 33759685 - 2
Clinical Case Seminar: Postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis.
Mamoojee Y, Ganguri M, Taylor N, Quinton R
Clinical endocrinology 2018; (88(1)):13-20 doi:10.1111/cen.13492.
PMID: 28980338 - 3
Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies.
Yance VRV, Marcondes JAM, Rocha MP, et al.
European journal of endocrinology 2017; (177(1)):93-102.
PMID: 28432270 - 4
A Case of Ovarian Hyperthecosis in a Postmenopausal Woman.
Yousaf S, Nizar R, John L, Simpson A
JCEM case reports 2023; (1(6)):luad148 doi:10.1210/jcemcr/luad148.
PMID: 38077307 - 5
Ovarian stromal hyperthecosis: An underestimated virilizing disorder in postmenopausal women.
Boudaouara O, Sellami A, Roger P
Annales d'endocrinologie 2025; (86(5)):101800 doi:10.1016/j.ando.2025.101800.
PMID: 40513985 - 6
A benign cause of hyperandrogenism in a postmenopausal woman.
Roque JJN, Alves IBS, Rodrigues AMAPF, Bugalho MJ
Endocrinology, diabetes & metabolism case reports 2021; (2021()).
PMID: 33597312 - 7
Presumptive ovarian hyperthecosis in an adolescent girl with sustained remission after oral contraceptive therapy: a 23-year follow-up case report.
Frank GR
Journal of pediatric endocrinology & metabolism : JPEM 2026; (39(7)):716-721 doi:10.1515/jpem-2026-0052.
PMID: 42051067 - 8
Severe hyperandrogenism due to ovarian hyperthecosis in a young woman.
Goyal A, Malhotra R, Kulshrestha V, Kachhawa G
BMJ case reports 2019; (12(12)) doi:10.1136/bcr-2019-232783.
PMID: 31852694 - 9
Ovarian Hyperthecosis in a 12-year-old Chinese Girl Presenting With Virilization.
Lai TS, Wong EW, Hui HF, Wong LM
JCEM case reports 2024; (2(1)):luad140 doi:10.1210/jcemcr/luad140.
PMID: 38106845 - 10
Ovarian hyperthecosis in adolescent females: two case reports and a review of the literature.
Angley E, Vollenhoven B, White M
Journal of pediatric endocrinology & metabolism : JPEM 2024; (37(9)):829-834 doi:10.1515/jpem-2024-0223.
PMID: 39066630 - 11
Androgen excess: Investigations and management.
Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R
Best practice & research. Clinical obstetrics & gynaecology 2016; (37()):98-118 doi:10.1016/j.bpobgyn.2016.05.003.
PMID: 27387253 - 12
Value of selective venous catheterization in the diagnosis of hyperandrogenism.
Hickman LC, Goodman L, Falcone T
Fertility and sterility 2017; (108(6)):1085 doi:10.1016/j.fertnstert.2017.08.037.
PMID: 29100622 - 13
Ovarian Hyperthecosis Presenting With Postmenopausal Virilization and New-Onset Type 2 Diabetes.
Knott JA, Morris J
JCEM case reports 2025; (3(7)):luaf118 doi:10.1210/jcemcr/luaf118.
PMID: 40443457
This page explains treatment choices and symptom reversibility in ovarian stromal hyperthecosis for informational purposes only and does not constitute medical advice. Discuss fertility, surgery, medication monitoring, and hormone changes with your endocrinologist and gynecologic surgeon.
Get notified when new evidence is published on ovarian stromal hyperthecosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.